Cite
HARVARD Citation
Soumerai, J. et al. (2021). Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet. 8 (12), pp. e879-e890. [Online].